Literature DB >> 29698806

Identification of two 14q32 deletions involving DICER1 associated with the development of DICER1-related tumors.

John C Herriges1, Sara Brown2, Maria Longhurst2, Jillian Ozmore3, John B Moeschler4, Aura Janze5, Jeanne Meck5, Sarah T South6, Erica F Andersen6.   

Abstract

DICER1 encodes an RNase III endonuclease protein that regulates the production of small non-coding RNAs. Germline mutations in DICER1 are associated with an autosomal dominant hereditary cancer predisposition syndrome that confers an increased risk for the development of several rare childhood and adult-onset tumors, the most frequent of which include pleuropulmonary blastoma, ovarian sex cord-stromal tumors, cystic nephroma, and thyroid gland neoplasia. The majority of reported germline DICER1 mutations are truncating sequence-level alterations, suggesting that a loss-of-function type mechanism drives tumor formation in DICER1 syndrome. However, reports of patients with germline DICER1 whole gene deletions are limited, and thus far, only two have reported an association with tumor development. Here we report the clinical findings of three patients from two unrelated families with 14q32 deletions that encompass the DICER1 locus. The deletion identified in Family I is 1.4 Mb and was initially identified in a 6-year-old male referred for developmental delay, hypotonia, macrocephaly, obesity, and behavioral problems. Subsequent testing revealed that this deletion was inherited from his mother, who had a clinical history that included bilateral multinodular goiter and papillary thyroid carcinoma. The second deletion is 5.0 Mb and was identified in a 15-year-old female who presented with autism, coarse facial features, Sertoli-Leydig cell tumor, and Wilms' tumor. These findings provide additional supportive evidence that germline deletion of DICER1 confers an increased risk for DICER1-related tumor development, and provide new insight into the clinical significance of deletions involving the 14q32 region.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  14q32 deletion; Cancer; DICER1 syndrome

Mesh:

Substances:

Year:  2018        PMID: 29698806     DOI: 10.1016/j.ejmg.2018.04.011

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  6 in total

Review 1.  Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes.

Authors:  Vania Nosé; Anthony Gill; José Manuel Cameselle Teijeiro; Aurel Perren; Lori Erickson
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

2.  PUMILIO competes with AUF1 to control DICER1 RNA levels and miRNA processing.

Authors:  Swetha Rajasekaran; Eshan Khan; Samuel R Ching; Misbah Khan; Jalal K Siddiqui; Daniela F Gradia; Chenyu Lin; Stephanie J Bouley; Dayna L Mercadante; Amity L Manning; André P Gerber; James A Walker; Wayne O Miles
Journal:  Nucleic Acids Res       Date:  2022-06-23       Impact factor: 19.160

Review 3.  Spectrum of DICER1 Germline Pathogenic Variants in Ovarian Sertoli-Leydig Cell Tumor.

Authors:  Elisa De Paolis; Rosa Maria Paragliola; Paola Concolino
Journal:  J Clin Med       Date:  2021-04-23       Impact factor: 4.241

Review 4.  Inherited Follicular Epithelial-Derived Thyroid Carcinomas: From Molecular Biology to Histological Correlates.

Authors:  José Manuel Cameselle-Teijeiro; Ozgur Mete; Sylvia L Asa; Virginia LiVolsi
Journal:  Endocr Pathol       Date:  2021-01-25       Impact factor: 3.943

5.  A complex DICER1 syndrome phenotype associated with a germline pathogenic variant affecting the RNase IIIa domain of DICER1.

Authors:  Emeli Pontén; Sofia Frisk; Fulya Taylan; Raquel Vaz; Sandra Wessman; Leanne de Kock; Niklas Pal; William D Foulkes; Kristina Lagerstedt-Robinson; Ann Nordgren
Journal:  J Med Genet       Date:  2020-11-18       Impact factor: 6.318

6.  Unusual phenotypes in patients with a pathogenic germline variant in DICER1.

Authors:  Kateryna Venger; Miriam Elbracht; Julia Carlens; Peter Deutz; Felix Zeppernick; Lisa Lassay; Christian Kratz; Martin Zenker; Jung Kim; Douglas R Stewart; Ilse Wieland; Kris Ann P Schultz; Nicolaus Schwerk; Ingo Kurth; Udo Kontny
Journal:  Fam Cancer       Date:  2021-07-31       Impact factor: 2.446

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.